SEC Form 4 · accession 0001209191-15-085460
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sharon Mates
Officer — Chairman, President & CEO · Director
Period of report
Dec 11, 2015
Accepted (ET)
Dec 15, 2015 · 8:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 11, 2015 | M | 25,000 | $0.60 | A | 1,093,935 | D | |
| Common Stock | Dec 11, 2015 | M | 25,000 | $1.36 | A | 1,118,935 | D | |
| Common Stock | Dec 11, 2015 | M | 18,750 | $1.50 | A | 1,137,685 | D | |
| Common StockF2 | Dec 11, 2015 | S | 30,046 | $53.56 | D | 1,107,639 | D | |
| Common StockF3 | Dec 11, 2015 | S | 19,654 | $54.24 | D | 1,087,985 | D | |
| Common StockF4 | Dec 11, 2015 | S | 1,800 | $55.08 | D | 1,086,185 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $0.60 | Dec 11, 2015 | M | 25,000 | D | — | Dec 14, 2015 | Common Stock | 25,000 | 0 | D |
| Stock Option (right to buy)F5 | $1.36 | Dec 11, 2015 | M | 25,000 | D | — | Dec 5, 2016 | Common Stock | 25,000 | 0 | D |
| Stock Option (right to buy)F5 | $1.50 | Dec 11, 2015 | M | 18,750 | D | — | Dec 12, 2017 | Common Stock | 18,750 | 18,750 | D |
Explanation of responses
- F1The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2015. A majority of the proceeds from these sales will be used to cover the reporting person's tax liability arising from option exercises.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.95 to $53.94, inclusive.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.97 to $54.96, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.97 to $55.24, inclusive.
- F5All shares underlying this option have vested.
Remarks
The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4.